Method of and device for therapeutic illumination of internal organs and tissues

• US 20040073278A1
• Filed: 08/04/2003
• Published: 04/15/2004
• Est. Priority Date: 09/04/2001
• Status: Abandoned Application

• Current Assignee: AMIT Technology Science & Medicine Limited
• Original Assignee: AMIT Technology Science & Medicine Limited
• Inventors: Pachys, Freddy
• Application Number:
  US10/466,776
• Publication Number:
  US 20040073278A1
• Time in Patent Office: Days
• US Class Current: 607/88
• CPC Class Codes: A61N 2005/063 comprising light transmitting means, e.g. optical fibres
• CPC Class Codes: A61N 5/0601 Apparatus for use inside the body
• CPC Class Codes: A61N 5/0618 Psychological treatment

Abstract

Methods and devices for intracorporeal therapeutic illumination using an implantable light source are disclosed. The present invention can be used for short, intermediate and/or long-term light therapy of all internal tissues, organs and organ surfaces, including the blood, in the treatment of inflammatory, infectious, arthritic, allergic, musculoskeletal and parasitic pathologies. The implantable light source comprises a wide range of modifiable wavelengths and other light therapy parameters and can illuminate remote intracorporeal locations via optional fiber optic connection. Direct phototherapy of the blood is effected by implantable intravascular light sources, optical fiber conduits, a unique light source-bearing intravascular tubular platform or a novel, light emitting vascular prosthesis. Power and modulation of the light therapy parameters is provided by implantable power and control modules or, in preferred embodiments, by external sources in telemetric communication with the implanted light source. Light therapy parameters for individual treatment protocols can be precisely modulated in response to the physiological status of the patient, feedback from the tissues being treated or other, external stimuli.

Claims

1. A method of therapeutic illumination of internal organs and/or tissues, the method comprising implanting intracorporeally in a subject in need of therapeutic illumination an implantable light source for producing light suitable for therapeutic illumination.

2. The method of claim 1, wherein said implantable light source is in optical communication with an optical fiber for propagating light emitted from said light source to a remote intracorporeal location.

3. The method of claim 1, wherein said implantable light source is designed, constructed and implantable so as to illuminate a lumen of a blood vessel.

4. The method of claim 1, wherein said implantable light source is designed, constructed and implantable so as to illuminate a lumen of at least one heart chamber.

5. The method of claim 1, wherein said implantable light source is designed, constructed and implantable so as to illuminate a lumen of an organ.

6. The method of claim 5, wherein said organ is selected from the group consisting of the brain, spinal canal, sinuses, middle ear, lungs, esophagus, stomach, intestines, colon, pancreas, spleen, gall bladder, appendix, liver, kidney, bladder, heart, ovary and uterus.

7. The method of claim 1, wherein said implantable light source is designed, constructed and implantable so as to illuminate a surface of an internal organ.

8. The method of claim 7, wherein said organ is selected from the group consisting of eye, brain, spinal cord, sinuses, middle ear, lungs, stomach, intestines, pancreas, spleen, liver, kidney, heart, ovary, uterus, testis, prostate, bladder, endocrine and/or exocrine glands, bone, muscle and connective tissue.

9. The method of claim 1, wherein said light is a coherent light between 189 nm and 1,300 nm in wavelength.

10. The method of claim 1, wherein said light is a non-coherent light of a plurality of wavelengths and/or wavebands between 189 nm and 1,300 nm.

11. The method of claim 1, wherein said light is a non-coherent light of at least one waveband between 189 nm and 1,300 nm.

12. The method of claim 1, wherein said implantable light source comprises a tubular platform and a light source physically connected thereto.

13. The method of claim 12, wherein said tubular platform is transparent to light produced by said light source.

14. The method of claim 12, wherein said tubular platform is opaque to light produced by said light source.

15. The method of claim 1, wherein said implantable light source is powered by an intracorporeally implantable battery or energy transducer.

16. The method of claim 15, wherein said energy transducer is selected from the group consisting of a radiofrequency transducer, a magnetic transducer and an acoustic transducer.

17. The method of claim 1, wherein said implantable light source comprises and is powered by a battery or energy transducer integrally connected thereto.

18. The method of claim 17, wherein said energy transducer is selected from the group consisting of a radiofrequency transducer, a magnetic transducer and an acoustic transducer.

19. The method of claim 1, wherein said implantable light source is powered by telemetry.

20. The method of claim 19, wherein said telemetry is selected from the group consisting of acoustic based telemetry, radiofrequency based telemetry and magnetic based telemetry.

21. The method of claim 1, wherein said implantable light source is controlled, said control comprising determining light therapy parameters selected from a group comprising dose, intensity, frequency, pulse duration, wavelength, power, monochromaticity, intensity modulation with specific endogenous frequencies and three dimensional photon distribution.

22. The method of claim 21, wherein said light therapy parameters are preselected.

23. The method of claim 21, wherein said light therapy parameters are variably determined.

24. The method of claim 23, wherein said light therapy parameters are determined in respect to a physiological status of a subject being treated.

25. The method of claim 24, wherein said physiological status is selected from the group consisting of EEG, EMG, ECG, blood chemistry, viral load, body temperature, chemiluminescence, pH, pulse and respiration.

26. The method of claim 1, wherein said implantable light source is controlled by telemetry.

27. The method of claim 26, wherein said telemetry is selected from the group consisting of acoustic-based telemetry, radiofrequency-based telemetry and magnetic-based telemetry.

28. The method of claim 1, wherein said implantable light source is controlled by an on-board logic-chip.

29. The method of claim 1, wherein said subject is treated for a pathology selected from the group consisting of inflammations, wounds, burns, chronic ulceration'"'"'s, eczema, shingles, infection, scars, skin, vascular and organ grafts, gingival irritation, oral ulcers, cellulite, arthritic conditions, muscle pain and stiffness, myofascial pain, swelling, inflammation, scarring and stiffness, sprains, strains, wounds, whiplash, repetitive strain injuries, neurological and neuromuscular conditions, jet lag, Seasonal Affective Disorder, shift work sleep disturbance, atheroslerosis following balloon angioplasty, allergic rhinitis and nasal polyposis.

30. The method of claim 1, wherein said subject is treated for a pathology selected from the group consisting of diabetic angiopathy, IDDM, chronic foot ulcers, ischemic heart disease, rheumatoid arthritis, autonomic vascular dystonia, atherosclerosis, a typical pneumonia, poliomyelitis and polioencephalitis, hepatitis, HIV, AIDS, influenza, common upper respiratory diseases, herpes simplex and zoster, mumps, mononucleosis, measles, porphyria, hyperbilirubinemia and parasitic infections.

31. A method of therapeutic illumination of blood, the method comprising implanting intracorporeally in a subject in need of therapeutic illumination of blood an implantable light source for producing light suitable for therapeutic illumination of blood.

32. The method of claim 31, wherein said implantable light source is in optical communication with an optical fiber for propagating light emitted from said light source to a remote intracorporeal location.

33. The method of claim 31, wherein said implantable light source is designed, constructed and implantable so as to illuminate a lumen of a blood vessel.

34. The method of claim 31, wherein said implantable light source is designed, constructed and implantable so as to illuminate a lumen of at least one heart chamber.

35. The method of claim 31, wherein said light is a coherent light between 189 nm and 1,300 nm in wavelength.

36. The method of claim 31, wherein said light is a non-coherent light of a plurality of wavelengths and/or wavebands between 189 nm and 1,300 nm.

37. The method of claim 31, wherein said light is a non-coherent light of at least one waveband between 189 nm and 1,300 nm.

38. The method of claim 31, wherein said implantable light source comprises a tubular platform and a light source physically connected thereto, said tubular platform is designed and constructed to be engaged within a blood vessel.

39. The method of claim 38, wherein said tubular platform is transparent to light produced by said light source.

40. The method of claim 38, wherein said tubular platform is opaque to light produced by said light source.

41. The method of claim 31, wherein said implantable light source is powered by an intracorporeally implantable battery or energy transducer.

42. The method of claim 41, wherein said energy transducer is selected from the group consisting of a radiofrequency transducer, a magnetic transducer and an acoustic transducer.

43. The method of claim 31, wherein said implantable light source comprises and is powered by a battery or energy transducer integrally connected thereto.

44. The method of claim 43, wherein said energy transducer is selected from the group consisting of a radiofrequency transducer, a magnetic transducer and an acoustic transducer.

45. The method of claim 31, wherein said implantable light source is powered by telemetry.

46. The method of claim 45, wherein said telemetry is selected from the group consisting of acoustic based telemetry, radiofrequency based telemetry and magnetic based telemetry.

47. The method of claim 31, wherein said implantable light source is controlled, said control comprising determining light therapy parameters selected from a group comprising dose, intensity, frequency, pulse duration, wavelength, power, monochromaticity, intensity modulation with specific endogenous frequencies and three dimensional photon distribution.

48. The method of claim 47, wherein said light therapy parameters are preselected.

49. The method of claim 47, wherein said light therapy parameters are variably determined.

50. The method of claim 47, wherein said light therapy parameters are determined in respect to a physiological status of a subject being treated.

51. The method of claim 50, wherein said physiological status is selected from the group consisting of EEG, EMG, ECG, blood chemistry, viral load, body temperature, chemiluminescence, pH, pulse and respiration.

52. The method of claim 31, wherein said implantable light source is controlled by telemetry.

53. The method of claim 52, wherein said telemetry is selected from the group consisting of acoustic-based telemetry, radiofrequency-based telemetry and magnetic-based telemetry.

54. The method of claim 31, wherein said implantable light source is controlled by an on-board logic-chip.

55. The method of claim 31, wherein said subject is treated for a pathology selected from the group consisting of diabetic angiopathy, IDDM, chronic foot ulcers, ischemic heart disease, rheumatoid arthritis, autonomic vascular dystonia, atherosclerosis, a typical pneumonia, poliomyelitis and polioencephalitis, hepatitis, HIV, AIDS, influenza, common upper respiratory diseases, herpes simplex and zoster, mumps, mononucleosis, measles, porphyria, hyperbilirubinemia and parasitic infections.

56. A device for therapeutic illumination of internal organs and/or tissues, the device comprising:

a light source for producing light suitable for therapeutic illumination;

a battery or energy transducer for powering said light source;

at least one optical fiber in optical communication with said light source for propagating light emitted from said light source to a remote intracorporeal location;

wherein said light source, said battery or energy transducer and said at least one optical fiber are designed and constructed for intracorporeal implantation.

57. The device of claim 56, designed, constructed and implantable so as to illuminate a lumen of a blood vessel.

58. The device of claim 56, designed, constructed and implantable so as to illuminate a lumen of at least one heart chamber.

59. The device of claim 56, designed, constructed and implantable so as to illuminate a lumen of an organ.

60. The device of claim 59, wherein said organ is selected from the group consisting of the brain, spinal canal, sinuses, middle ear, lungs, esophagus, stomach, intestines, colon, pancreas, spleen, gall bladder, appendix, liver, kidney, bladder, heart, ovary and uterus.

61. The device of claim 56, designed, constructed and implantable so as to illuminate a surface of an internal organ.

62. The device of claim 61, wherein said organ is selected from the group consisting of the eye, brain, spinal cord, sinuses, middle ear, lungs, stomach, intestines, pancreas, spleen, liver, kidney, heart, ovary, uterus, testis, prostate, bladder, endocrine and/or exocrine glands, bone, muscle and connective tissue.

63. The device of claim 56, wherein said light is a coherent light between 189 nm and 1,300 nm in wavelength.

64. The device of claim 56, wherein said light is a non-coherent light of a plurality of wavelengths and/or wavebands between 189 nm and 1,300 nm.

65. The device of claim 56, wherein said light is a non-coherent light of at least one waveband between 189 nm and 1,300 nm.

66. The device of claim 56, further comprising a tubular platform carrying said light source.

67. The device of claim 66, wherein said tubular platform is transparent to light produced by said light source.

68. The device of claim 66, wherein said tubular platform is opaque to light produced by said light source.

69. The device of claim 56, wherein said energy transducer is selected from the group consisting of a radiofrequency transducer, a magnetic transducer and an acoustic transducer.

70. The device of claim 56, wherein said light source is powered by telemetry.

71. The device of claim 70, wherein said telemetry is selected from the group consisting of acoustic based telemetry, radiofrequency based telemetry and magnetic based telemetry.

72. The device of claim 56, wherein said implantable light source is controlled, said control comprising determining light therapy parameters selected from a group comprising dose, intensity, frequency, pulse duration, wavelength, power, monochromaticity, intensity modulation with specific endogenous frequencies and three dimensional photon distribution.

73. The device of claim 72, wherein said light therapy parameters are preselected.

74. The device of claim 72, wherein said light therapy parameters are variably determined.

75. The device of claim 74, wherein said light therapy parameters are determined in respect to a physiological status of a subject being treated.

76. The device of claim 75, wherein said physiological status is selected from the group consisting of EEG, EMG, ECG, blood chemistry, viral load, body temperature, chemiluminescence, pH, pulse and respiration.

77. The device of claim 56, wherein said light source is controlled by telemetry.

78. The device of claim 77, wherein said telemetry is selected from the group consisting of acoustic-based telemetry, radiofrequency-based telemetry and magnetic-based telemetry.

79. The device of claim 56, wherein said light source is controlled by an on-board logic-chip.

80. The device of claim 56, indicated for treatment of a pathology selected from the group consisting of inflammations, wounds, burns, chronic ulcerations, eczema, shingles, infection, scars, skin, vascular and organ grafts, gingival irritation, oral ulcers, cellulitis, arthritic conditions, muscle pain and stiffness, myofascial pain, swelling, inflammation, scarring and stiffness, sprains, strains, wounds, whiplash, repetitive strain injuries, neurological and neuromuscular conditions, jet lag, Seasonal Affective Disorder, shift work sleep disturbance, atheroslerosis following balloon angioplasty, allergic rhinitis and nasal polyposis.

81. The device of claim 56, indicated for treatment of a pathology selected from the group consisting of diabetic angiopathy, IDDM, chronic foot ulcers, ischemic heart disease, rheumatoid arthritis, autonomic vascular dystonia, atherosclerosis, a typical pneumonia, poliomyelitis and polioencephalitis, hepatitis, HIV, AIDS, influenza, common upper respiratory diseases, herpes simplex and zoster, mumps, mononucleosis, measles, porphyria, hyperbilirubinemia and parasitic infections.

82. The device of claim 56, wherein said light source is a non-gaseous light emitting source.

83. The device of claim 82, wherein said non-gaseous light source is selected form the group consisting of laser, light-emitting diodes, superluminous diodes and laser diodes.

84. The device of claim 56, wherein said at least one optical fiber is capable of adapting to the contour of body passages.

85. The device of claim 56, wherein said at least one optical fiber forms a bundle of optical fibers.

86. The device of claim 85, wherein said bundle of optical fibers is flexible and hence capable of adapting to contours of body passages.

87. The device of claim 85, wherein said bundle of optical fibers is engaged within a sheath.

88. The device of claim 56, wherein said at least one optical fiber forms a bundle of optical fibers designed for simultaneously delivering light to a plurality of intracorporeal locations.

89. A device for therapeutic illumination of a tissue and/or an organ, the device comprising:

an implantable vascular prosthesis capable of anastamosing connection to a blood vessel in which a lateral or terminal opening has been formed;

a light source for producing light suitable for therapeutic illumination being optically connected to said vascular prosthesis; and

an implantable battery or energy transducer for powering said light source.

90. The device of claim 89, wherein said light is a coherent light between 189 nm and 1,300 nm in wavelength.

91. The device of claim 89, wherein said light is a non-coherent light of a plurality of wavelengths and/or wavebands between 189 nm and 1,300 nm.

92. The device of claim 89, wherein said light is a non-coherent light of at least one waveband between 189 nm and 1,300 nm.

93. The device of claim 89, wherein said energy transducer is selected from the group consisting of a radiofrequency transducer, a magnetic transducer and an acoustic transducer.

94. The device of claim 89, wherein said light source is powered by telemetry.

95. The device of claim 94, wherein said telemetry is selected from the group consisting of acoustic based telemetry, radiofrequency based telemetry and magnetic based telemetry.

96. The device of claim 89, wherein said light source is controlled, said control comprising determining light therapy parameters selected from a group comprising dose, intensity, frequency, pulse duration, wavelength, power, monochromaticity, intensity modulation with specific endogenous frequencies and three dimensional photon distribution.

97. The device of claim 96, wherein said light therapy parameters are preselected.

98. The device of claim 96, wherein said light therapy parameters are variably determined.

99. The device of claim 98, wherein said light therapy parameters are determined in respect to a physiological status of a subject being treated.

100. The device of claim 99, wherein said physiological status is selected from the group consisting of EEG, EMG, ECG, blood chemistry, viral load, body temperature, chemiluminescence, pH, pulse and respiration.

101. The device of claim 89, wherein said light source is controlled by telemetry.

102. The device of claim 101, wherein said telemetry is selected from the group consisting of acoustic-based telemetry, radiofrequency-based telemetry and magnetic-based telemetry.

103. The device of claim 89, wherein said light source is controlled by an on-board logic-chip.

104. The device of claim 89, indicated for treatment of a pathology selected from the group consisting of inflammations, wounds, burns, chronic ulcerations, eczema, shingles, infection, scars, skin, vascular and organ grafts, gingival irritation, oral ulcers, cellulitis, arthritic conditions, muscle pain and stiffness, myofascial pain, swelling, inflammation, scarring and stiffness, sprains, strains, wounds, whiplash, repetitive strain injuries, neurological and neuromuscular conditions, jet lag, Seasonal Affective Disorder, shift work sleep disturbance, atheroslerosis following balloon angioplasty, allergic rhinitis and nasal polyposis.

105. The device of claim 89, indicated for treatment of a pathology selected from the group consisting of diabetic angiopathy, IDDM, chronic foot ulcers, ischemic heart disease, rheumatoid arthritis, autonomic vascular dystonia, atherosclerosis, a typical pneumonia, poliomyelitis and polioencephalitis, hepatitis, HIV, AIDS, influenza, common upper respiratory diseases, herpes simplex and zoster, mumps, mononucleosis, measles, porphyria, hyperbilirubinemia and parasitic infections.

106. The device of claim 89, wherein said light source is a non-gaseous light emitting source.

107. The device of claim 106, wherein said non-gaseous light source is selected form the group consisting of laser, light-emitting diodes, superluminous diodes and laser diodes.

108. The device of claim 89, wherein said vascular prosthesis contains at least one optical fiber in optical connection with said light source.

109. The device of claim 108, wherein said at least one optical fiber forms a bundle of optical fibers.

110. The device of claim 109, wherein said bundle of optical fibers is flexible and hence capable of adapting to contours of body passages.

111. The device of claim 109, wherein said bundle of optical fibers is engaged within a sheath.

112. The device of claim 89, wherein said at least one optical fiber forms a bundle of optical fibers designed for simultaneously delivering light to a plurality of intracorporeal locations.

113. A device for therapeutic illumination of blood, the device comprising an implantable vascular prosthesis capable of anastamosing connection to a blood vessel in which a lateral or terminal opening has been formed, said implantable vascular prosthesis having an internal light emitting surface for light irradiation of substances in fluid motion through said prosthesis.

114. A device for therapeutic illumination of blood, the device comprising:

an implantable tubular platform allowing blood flow therethrough;

a light source for producing light suitable for therapeutic illumination being carried by said implantable tubular platform; and

an implantable battery or energy transducer for powering said light source.

115. The device of claim 114, wherein said light is a coherent light between 189 nm and 1,300 nm in wavelength.

116. The device of claim 114, wherein said light is a non-coherent light of a plurality of wavelengths and/or wavebands between 189 nm and 1,300 nm.

117. The device of claim 114, wherein said light is a non-coherent light of at least one waveband between 189 nm and 1,300 nm.

118. The device of claim 114, wherein said tubular platform is transparent to light produced by said light source.

119. The device of claim 114, wherein said tubular platform is opaque to light produced by said light source.

120. The device of claim 114, wherein said energy transducer is selected from the group consisting of a radiofrequency transducer, a magnetic transducer and an acoustic transducer.

121. The device of claim 114, wherein said light source is powered by telemetry.

122. The device of claim 121, wherein said telemetry is selected from the group consisting of acoustic based telemetry, radiofrequency based telemetry and magnetic based telemetry.

123. The device of claim 114, wherein said light source is controlled, said control comprising determining light therapy parameters selected from a group comprising dose, intensity, frequency, pulse duration, wavelength, power, monochromaticity, intensity modulation with specific endogenous frequencies and three dimensional photon distribution.

124. The device of claim 123, wherein said light therapy parameters are preselected.

125. The device of claim 123, wherein said light therapy parameters are variably determined.

126. The device of claim 125, wherein said light therapy parameters are determined in respect to a physiological status of a subject being treated.

127. The device of claim 126, wherein said physiological status is selected from the group consisting of EEG, EMG, ECG, blood chemistry, viral load, body temperature, chemiluminescence, pH, pulse and respiration.

128. The device of claim 114, wherein said light source is controlled by telemetry.

129. The device of claim 128, wherein said telemetry is selected from the group consisting of acoustic-based telemetry, radiofrequency-based telemetry and magnetic-based telemetry.

130. The device of claim 114, wherein said light source is controlled by an on-board logic-chip.

131. The device of claim 114, indicated for treatment of a pathology selected from the group consisting of inflammations, wounds, burns, chronic ulcerations, eczema, shingles, infection, scars, skin, vascular and organ grafts, gingival irritation, oral ulcers, cellulitis, arthritic conditions, muscle pain and stiffness, myofascial pain, swelling, inflammation, scarring and stiffness, sprains, strains, wounds, whiplash, repetitive strain injuries, neurological and neuromuscular conditions, jet lag, Seasonal Affective Disorder, shift work sleep disturbance, atheroslerosis following balloon angioplasty, allergic rhinitis and nasal polyposis.

132. The device of claim 114, indicated for treatment of a pathology selected from the group consisting of diabetic angiopathy, IDDM, chronic foot ulcers, ischemic heart disease, rheumatoid arthritis, autonomic vascular dystonia, atherosclerosis, a typical pneumonia, poliomyelitis and polioencephalitis, hepatitis, HIV, AIDS, influenza, common upper respiratory diseases, herpes simplex and zoster, mumps, mononucleosis, measles, porphyria, hyperbilirubinemia and parasitic infections.

133. The device of claim 114, wherein said light source is a non-gaseous light emitting source.

134. The device of claim 133, wherein said non-gaseous light source is selected form the group consisting of laser, light-emitting diodes, superluminous diodes and laser diodes.

135. The device of claim 114, wherein said tubular platform contains at least one optical fiber in optical connection with said light source.

136. The device of claim 135, wherein said at least one optical fiber forms a bundle of optical fibers.

137. The device of claim 136, wherein said bundle of optical fibers is flexible and hence capable of adapting to contours of body passages.

138. The device of claim 136, wherein said bundle of optical fibers is engaged within a sheath.

139. The device of claim 114, wherein said at least one optical fiber forms a bundle of optical fibers designed for simultaneously delivering light to a plurality of intracorporeal locations.